Covishield Vaccine Demonstrated More Robust Immune Response Compared to Covaxin: Study

 A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences (NCBS), has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin.

The Study Compared The Immunogenicity of Covishield and Covaxin, the two primary covid-19 vaccines wedly used in India.

The findings of the study, which have been published in the journey regional health health southeast asia, offer valuable insights into the quality and quantity of immmune Responses Inuduated BY CCCCINES Cov-2, with significant implications for shaping future vaccination strategies .

The key findings state that covishield, leveraging a virus vector to deliver the spike protein of the coronavirus, consistently demonstrated More Robust Immune Response Compared to Covaxin, Anactivated Viruscinine.

"Notably, Covishield Exhibited a Near-Complete Immune Response in the Majority of Participants, Whereas the Response to Covaxin was variable, particularly amon the-inoculated the inoculated beefore the emergency , "States the key findings released by ncbs.

The Study, Carried out from June 2021 to January 2022, Involved Assessing 691 Participants, Aged Between 18 and 45 years, from Bengaluru and Pune.

It examined their vaccination records and monitored their immune responses at different interval, bot prior to and following vaccination.

Covishield Elicited more t cells indicative of stronger immune response

Further, according to the key finding, covishield induced Higher antibody levels in bot serongative (individuals without prior expert) and seroposite (individuals with prior) ing a more potent and enduring immune response.

Covishield Elicited a Higher Number of T Cells Compared to Covaxin, Indicative of a Stronger Immune Response.

According to the Findings: “Covishield consistently exhibited Higher Level of Antibodies against Various Virus Strains Compared to Covaxin, Suggesting Its Potanical Supreorial SUPERION SUPEROTION ASINSTION AgA ICron ”.

“Follow-up study on vaccine immunology and the analysis of immune protection factors Wonds and, there's a scarcity of Comporative Studies on these two vaccines. This is one of the very few studies that not only investigations the immune respons of participants after vaccination, but also also considers their immune history prior to vaccination, "Said Dr. Mangaarkarasi Asokan, Former Program Head, Vacine (Vacine Immunology Studies-India outbreak -response network) and lead author of the study.

Prof. Satyajit Mayor, Scientist, NCBS-TIFR, said that this study was done at the height of the covid pandemic and reflected a collective sentiment to bring evidence-spoken-shaking to the outsing in the outsing, using in the utwn o indigenous vaccines that Were rolled out very Quickly for the Indian Population.

Lessons for future strategies

"The creation of a bio-resitory from the 15-month longitudinal study is invaluable. Analysis of the data and exploring the collected bio-resources will inform future immunizations strategies, at least for covid. Finally, the outcome of the study where the covishield vaccine was shown to outperform covaxin in all respects, should have important implications to strategies future Vaccination Drives, " Mayor said.